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ABSTRACT
Objectives: As Mycoplasma genitalium is associated
with pelvic inflammatory disease (PID), we examined the
efficacy of a commonly used PID antimicrobial in treating
M genitalium upper genital tract infection.
Methods: In the PID Evaluation and Clinical Health study
of inpatient versus outpatient treatment, 682 women
treated with cefoxitin and doxycycline for clinically
suspected PID had stored cervical and endometrial
specimens available for analysis. In the current sub study,
we compared baseline endometritis, short term treatment
failure (continued endometritis and pelvic pain 30 days
following treatment) and sequelae among women with
and without M genitalium, identified using PCR.
Results: Endometrial M genitalium was associated with
baseline endometritis (adjusted OR 3.0, 95% CI 1.5 to
6.1). Among women with a positive baseline
M genitalium test, 41% tested positive again 30 days
following treatment. Women testing positive compared to
those testing negative for M genitalium at baseline had an
increased risk of short-term treatment failure (RR 4.6,
95% CI 1.1 to 20.1). Rates of sequelae, including infertility
(22%), recurrent PID (31%) and chronic pelvic pain (42%),
were high among women testing positive for endometrial
M genitalium at baseline. There was a non-significant
trend towards increased infertility, chronic pelvic pain and
recurrent PID, and decreased pregnancy and live birth
following M genitalium infection.
Conclusions: M genitalium is associated with endome-
tritis and short-term PID treatment failure. Cefoxitin and
doxycycline, a Centers for Disease Control and Prevention
recommended PID treatment regimen, is ineffective for
the treatment of M genitalium upper genital tract
infection.
Mycoplasma genitalium was first identified in the
early 1980s among men with non-gonococcal
urethritis.
1 Because this pathogen is extremely
difficult to culture, only with polymerase chain
reaction (PCR) technology has research into
M genitalium pathogenicity progressed. Numerous
studies have confirmed the role of M genitalium in
drug resistant non-gonococcal urethritis,
23 and
some have also linked M genitalium with cervici-
tis
45 independent of Chlamydia trachomatis and
Neisseria gonorrhoeae. Cervicitis is considered a risk
factor for progression to pelvic inflammatory
disease (PID)—the common infection and inflam-
mation of the female upper genital tract, which
may lead to major reproductive morbidity includ-
ing infertility.
6
Although PID has polymicrobial aetiology, with
C trachomatis and/or N gonorrhoeae accounting for
approximately a third to a half of cases,
78up to
70% of PID cases have an unidentified aetiology.
Bacterial vaginosis-associated organisms have been
associated with PID,
91 0and because M genitalium is
associated with cervicitis
45 it is reasonable to
hypothesise that it also causes PID. Indeed, this
organism induces salpingitis in monkeys,
11 causes
morphological changes in ciliated fallopian tube
cells
12 and has been detected in fallopian tube tissue
in a woman with salpingitis.
13 Whereas studies
have associated M genitalium with PID and
endometritis,
14–16 the efficacy of commonly used
PID antimicrobials in treating M genitalium upper
genital tract infection is unknown.
MATERIALS AND METHODS
Patient population
Women who participated in the PID Evaluation and
Clinical Health (PEACH) Study and had previously
collected and stored cervical and endometrial speci-
mens were studied. The PEACH Study methods
have been described in detail elsewhere.
7 Briefly,
women aged 14 to 37 years were recruited between
March 1996 and February 1999 from emergency
departments, obstetrics and gynaecology clinics,
sexually transmitted disease (STD) clinics and
private practices at 13 US clinical sites. Altogether,
831women withclinicallysuspectedPID,definedby
pelvicpainoflessthan30daysduration,pelvicorgan
tenderness and leukorrhea, mucopurulent cervicitis
or untreated cervicitis were enrolled. For this
subsequent M genitalium study, stored endometrial
and cervical specimens were available for 611 and
682 of participants, respectively.
Randomisation and treatment
Patients in the parent PEACH study were rando-
mised to inpatient or outpatient antibiotic treat-
ment. The inpatient regimen consisted of cefoxitin
(2 g) parenterally every 6 hours and doxycycline
(100 mg) orally twice a day for a total of 14 days.
The outpatient regimen consisted of a single dose
of cefoxitin (2 g) intramuscularly plus probenecid
(1 g) orally, then doxycycline (100 mg) to be taken
orally twice a day for 14 days. As treatment
modality was not associated with reproductive
morbidities in the PEACH study,
7 we do
not distinguish between inpatient and outpatient
regimens or include them as a covariate in these
analyses.
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Previously collected cervical and endometrial specimens stored
at 270uC were tested for M genitalium using the MgPa-IMW
PCR assay targeting the MgPa gene
17 by technicians masked to
endometrial histology, treatment failure and reproductive
sequelae. This assay has an analytical sensitivity of 15 genomes
17
and a high clinical sensitivity and specificity relative to
transcription-mediated amplification (TMA)—another M geni-
talium NAAT assay.
18 For all samples testing positive, a second
MgPa PCR assay was performed using another aliquot of the
sample to rule out PCR product contamination or cross-
contamination; all samples initially positive were verified as
positive in this confirmatory test.
Endometrial biopsies and microbiological studies
At baseline and 30 days in the parent PEACH study, an
endometrial biopsy was obtained for histology, chlamydial PCR
(Roche Diagnostics, USA), and gonococcal culture. In a subset
of 352 women (240 women in the current sub study),
endometrial specimens were cultured for Mycoplasma hominis
and Ureaplasma urealyticum.
19 Endometrial histology was deter-
mined based on haematoxylin and eosin stained and methyl
green pyronine stained biopsy tissue specimens, read separately
by two reference pathologists who reviewed the slide together
to reach consensus upon disagreement. A modification
20 of the
criteria proposed by Kiviat et al
8 was used to define endome-
tritis. A classification of endometritis was given upon finding at
least five neutrophils in the endometrial surface epithelium in
the absence of menstrual endometrium and/or at least two
plasma cells in the endometrial stroma. Cervical swabs were
used for N gonorrhoeae cultures and C trachomatis PCR assays.
Vaginal smears were Gram stained for bacterial vaginosis as
described by Nugent et al.
10
Follow up
Participants were monitored with in-person visits at 5 and 30
days. Subsequent telephone interviews were conducted every 3
months during the first year and then every 4 months until June
2004, at which point we had follow up information for 541
women, representing a mean follow up of 84 months.
Reproductive outcomes included the occurrence of a first
pregnancy, first live birth, infertility, chronic pelvic pain and
recurrent PID. Infertility was defined when a sexually active
woman with at least 12 months of follow up did not report
conception (positive urine or blood test or doctor’s diagnosis of
pregnancy) despite rare or no use of a contraceptive method.
Chronic pelvic pain was defined as pain reported during at least
two consecutive follow up interviews; thereby, suggesting a
minimum of 6 months duration. Recurrent PID was self
reported and verified whenever medical records were available
(in 45% of the cohort). Recurrent PID was confirmed in 76% of
medical records and rates by self report and medical record
review were similar.
7 As few women experienced an ectopic
pregnancy during follow up (n=6), we did not include this as
an outcome.
Statistical methods
Baseline descriptive characteristics were compared between
women with and without M genitalium using x
2 tests of
proportions. The cross-sectional association between M genita-
lium and endometritis at baseline was additionally determined
using a logistic model, fit with M genitalium, age, race,
N gonorrhoeae and C trachomatis as explanatory variables.
Relative risks were calculated for the prospectively determined
outcomes. Incident endometritis was defined by a negative
histological test for endometritis at baseline followed by a
positive histological categorisation for endometritis 30 days
following treatment. To examine treatment failure, we cate-
gorised persistent endometritis as histological endometritis
identified at both the baseline and 30 day examinations. Log-
binomial regressions determined the relative risks and 95%
confidence intervals (CIs) for endometritis at 30 days, incident
endometritis, persistent endometritis, recurrent PID, infertility,
chronic pelvic pain, pregnancy and live birth, and included
M genitalium, age and race as explanatory variables. Infertility,
pregnancy and live birth models were additionally adjusted for
self reported infertility at baseline, and models predicting
treatment failure were additionally adjusted for intercourse
between baseline and 30 days and self reported partner
treatment. Analyses were conducted first using both cervical
and endometrial M genitalium PCR results combined and were
then repeated using only endometrial PCR. All analyses were
conducted in the entire cohort and in a subset of women with
negative tests for N gonorrhoeae or C trachomatis. SAS version 9.1
for Windows was used for all statistical comparisons.
RESULTS
We detected M genitalium in 88 (15%) of women at baseline.
Altogether, 11% of cervical specimens and 8% of endometrial
specimens were positive for M genitalium; infections at these
sites were highly correlated (Phi correlation 0.63, p,0.0001),
with 74% of endometrial positive cases also positive at the
cervix and 60% of cervical positive cases also positive in the
endometrium.
Women who tested positive compared to those who tested
negative for M genitalium were more than twice as likely to have
histologically confirmed endometritis at baseline (odds ratio
(OR) 2.6, 95% CI 1.5 to 4.6; table 1). After adjustment for age,
race, N gonorrhoeae and C trachomatis, women testing positive
for M genitalium were two times more likely to have baseline
endometritis (OR 2.0, 95% CI 1.0 to 4.2). Participants who
tested positive and negative for M genitalium had similar scores
for self rated pelvic pain at baseline. However, whereas women
who tested positive for M genitalium alone scored their pelvic
pain similarly to those who tested positive for C trachomatis
alone (p=0.5), women testing positive for M genitalium alone
had self rated pelvic pain scores, which were significantly lower
than those among women testing positive for N gonorrhoeae
alone at baseline (58.0 (SD 21.9) vs 72.3 (SD 23.9), p=0.01).
Women with versus those without M genitalium identified in
endometrial and/or cervical specimens were more likely to be
less than 25 years of age, have concurrent N gonorrhoeae and
C trachomatis, and report vaginal douching, drug use and
cigarette smoking (table 1).
Overall, 23 out of 56 women (41%) with M genitalium
identified in either the cervix and/or endometrium at baseline
had M genitalium persistently identified 30 days following
treatment. Of women with endometrial specimens obtained at
both baseline and 30 days, 44% (14/32) had persistent
endometrial M genitalium detected. Women with M genitalium
identified in the endometrium were 4.5 times more likely to
experience short-term treatment failure, defined by histological
identification of endometritis and persistent pelvic pain at the
30 day follow up clinic visit (adjusted rate ratio (RR) 4.6, 95%
CI 1.1 to 20.1; table 2). Having M genitalium identified in the
endometrium at baseline was associated with both an increased
risk of incident endometritis at 30 days (adjusted RR 5.0,
Clinical
Sex Transm Infect 2008;84:338–342. doi:10.1136/sti.2008.030486 33995% CI 1.2 to 20.6) and persistent endometritis, identified
histologically at both baseline and 30 days following treatment
(adjusted RR 4.1, 95% CI 1.4 to 11.9). In models additionally
adjusted for N gonorrhoeae and C trachomatis, endometrial
M genitalium was associated with incident endometritis
(adjusted RR 6.0, 95% CI 1.4 to 27.1) and treatment failure
(adjusted RR 5.2, 95% CI 0.9 to 30.6), although the association
with treatment failure was of borderline statistical significance.
Results were similar among a subset of women testing negative
for C trachomatis and N gonorrhoeae, although cell sizes were
small and confidence intervals large. In this group of women
without N gonorrhoeae or C trachomatis, those with M genitalium
identified in the endometrium at baseline were nearly nine
times as likely to be categorised as having endometritis at the 30
day examination (adjusted RR 8.8, 95% CI 2.0 to 39.6) and over
13 times as likely to be defined as having incident endometritis
at 30 days (adjusted RR 13.4, 2.4 to 75.2). As co-infection was
common in this study, models with microbiological interaction
terms were additionally examined. M genitalium did not
significantly interact with N gonorrhoeae or C trachomatis to
additionally influence the risk of incident endometritis or
treatment failure. In models adjusting for M hominis and
U urealyticum, M genitalium was associated with almost a 2.5-
fold increased risk of persistent endometritis (RR 2.4, 95% CI 0.5
to 12.4). However, as M hominis and U urealyticum were only
cultured on a subset of women in the parent PEACH study, a
smaller sample size resulted in a wide confidence interval.
Rates of infertility (22%), recurrent PID (31%) and chronic
pelvic pain (42%) were high among women testing positive for
endometrial M genitalium at baseline. Although the rates of
reproductive morbidity were not significantly higher among
women testing positive for M genitalium, all relationships were
in the hypothesised direction (table 3). Women with versus
those without endometrial M genitalium experienced modest,
non-significantly elevated risks of recurrent PID, infertility and
chronic pelvic pain, and were slightly but non-significantly less
likely to experience a pregnancy or live birth.
DISCUSSION
We detected M genitalium at a high prevalence (15%) among an
urban US population of women with non-gonococcal, non-
chlamydial PID, similar to that found in prior PID studies
among Kenyan (16%)
16 and UK women (13%).
15 In the PEACH
study, about 14% of women were infected with C trachomatis,
15% were infected with N gonorrhoeae and 5% were co-infected
with these two pathogens.
7 Thus, M genitalium was as prevalent
as C trachomatis or N gonorrhoeae among this population of
women with PID.
Women with endometrial M genitalium were over three times
more likely to have histologically confirmed endometritis
compared to women without M genitalium identified at this
site. Our study suggests that the relationship between
M genitalium and endometritis is independent and causal, since
among women without concurrent N gonorrhoeae and/or
C trachomatis, endometrial M genitalium was associated with
over a 13-fold risk of incident endometritis at the 30 day follow
up visit. Our results are consistent with previous cross-sectional
studies associating M genitalium with PID.
14 16 Further, we found
that although pelvic pain was similar between women testing
positive and negative for M genitalium, women who tested
positive for M genitalium alone reported significantly less pelvic
pain than women who tested positive for N gonorrhoeae alone.
Pelvic pain scores were lower and similar among women who
tested positive for M genitalium alone and C trachomatis alone,
suggesting that, like C trachomatis, M genitalium may also play a
role in asymptomatic or ‘‘silent’’ PID.
To our knowledge, ours is the first study to investigate
treatment failure among PID patients with M genitalium
identified in the endometrium. Persistence of M genitalium
following treatment with a standard Centers for Disease
Control and Prevention recommended PID treatment regimen
was very high: 44% of women with baseline endometrial
positive specimens tested positive again 30 days following
treatment. In contrast, only 2–4% of women in the PEACH
study had persistent or recurrent gonococcal or chlamydial
cervicitis when retested at 30 days.
7 Women with M genitalium
identified in the endometrium at baseline were four times as
likely to experience persistent endometritis and approximately
4.5 times as likely to experience treatment failure—defined as
the presence of both endometritis and pelvic pain 30 days
following treatment for PID.
Table 1 Characteristics of women with and without Mycoplasma
genitalium identified in the endometrium and/or cervix
Characteristic
Mg+ n=88,
n (%)
Mg2 n=498,
n (%) p Value
Histological endometritis* 43/63 (68.3) 197/439 (44.9) 0.0005
Pelvic pain score{ (mean SD) 67.7 (SD 21.3) 65.6 (SD 21.5) 0.392
Co-infection
N gonorrhoeae and/or
C trachomatis
43/65 (66.2) 172/435 (39.5) , 0.0001
N gonorrhoeae alone 26/59 (44.1) 111/423 (26.2) 0.0045
C trachomatis alone 23/74 (31.1) 91/484 (18.8) 0.0147
M hominis 4/37 (10.8) 17/203 (8.4) 0.6295
U urealyticum 1/37 (2.7) 15/203 (7.4) 0.2932
BV 51/80 (63.8) 254/453 (56.1) 0.2006
Demographic
Age
, 25 years 71/88 (80.7) 319/498 (64.1)
> 25 years 17/88 (19.3) 179/498 (35.9) 0.0023
Race/ethnicity
African American 69/88 (78.4) 358/498 (71.9)
White/Hispanic/Other 19/88 (21.6) 140/498 (28.1) 0.2047
Marital status
Unmarried 71/78 (91.0) 411/466 (88.2)
Married 7/78 (9.0) 55/466 (11.8) 0.4669
Education
, High school 38/88 (43.2) 189/497 (38.0)
> High school 50/88 (56.8) 308/497 (62.0) 0.3605
Sexual history
History of STD{ 51/86 (59.3) 288/485 (59.4) 0.9890
History of BV 13/86 (15.1) 117/482 (24.3) 0.0626
Sexually active 78/88 (88.6) 415/498 (83.3) 0.2095
Rare/occasional condom
use1
60/78 (76.9) 289/415 (69.6) 0.1943
Consistent condom use" 7/78 (9.0) 57/415 (13.7) 0.2511
> 2 sexual partners 10/88 (11.4) 46/498 (9.2) 0.5316
Behavioural
Vaginal douche, 2+ times
in past month
26/88 (29.6) 88/498 (17.7) 0.0095
Drug use 32/88 (36.4) 125/495 (25.3) 0.0304
Current smoker 49/88 (55.7) 194/495 (39.2) 0.0038
*>5 surface epithelium neutrophils per 6400 field absent of menstrual endometrium
and/or >2 stromal plasma cells per 6120 field; {mean composite pain score =
(mean of current pelvic pain score, average pelvic pain score and worst pelvic pain
score) 610; {history of Neisseria gonorrhoeae, Chlamydia trachomatis or
Trichonomas vaginalis; 1condoms used 0 to 5 out of 10 sexual encounters; "condoms
used in 10 out of 10 sexual encounters.
BV, bacterial vaginosis; STD, sexually transmitted disease.
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to cefoxitin and doxycycline. First, mycoplasmal bacteria lack a
cell wall and are thus resistant to cell wall inhibiting antibiotics.
Second, an M genitalium strain with increased tetracycline
resistance has been isolated
21 and M genitalium is associated with
persistent non-gonococcal urethritis among men treated with
tetracyclines.
22Mostwomen withPIDaretreatedwithantibiotics
directed toward N gonorrhoeae and/or Ct r a c h o m a t i s , despite the
fact that these pathogens account for only a third to a half of PID
cases. Indeed, in the PEACH study approximately 60% of women
had non-gonococcal, non-chlamydial PID.
7 Over a third of the
women had persistent endometritis post treatment,
7 identifying a
sizeable portion as having ongoing upper genital tract inflamma-
tionanddemonstratingthatantibioticsusedtotreatthiscritically
important upper tract syndrome are suboptimal. M genitalium has
demonstrated variable resistance to fluoroquinolones
23 and
susceptibility to macrolides, although azithromycin resistant
strains have recently been identified.
24 A newer quinolone,
moxifloxacin, has recently been shown to exhibit a high degree
of activity against M genitalium.
21 Randomised clinical trials
assessing these alternative regimens for the treatment of M
genitalium and PID are needed.
It is possible that other organisms resistant to doxycycline or
cefoxitin may have confounded the relationship between
M genitalium and persistent endometritis. However, M genita-
lium was not associated with endometrial M hominis or U
urealyticum—organisms that express tetracycline resistance
25 and
contain tetM genes that encode tetracycline resistance.
26
Further, adjustment for these pathogens only slightly attenu-
ated the relationship between M genitalium and persistent
endometritis. Additionally, we recognise that PID may recur
among women who engage in risky sexual behaviour during
treatment, and this may also confound treatment failure
comparisons. However, in models adjusted for self reported
partner treatment and intercourse, M genitalium was signifi-
cantly predictive of treatment failure, supporting the idea that
M genitalium antibiotic resistence may lead to persistent PID.
Although a positive M genitalium test was not significantly
predictive of reproductive morbidity in our study, results were
in the hypothesised direction. Infertility, chronic pelvic pain and
recurrent PID were more common among women testing
positive for endometrial M genitalium, and women who tested
positive were less likely to become pregnant or have a live birth.
Certainly, these reproductive outcomes are more subject to
misclassification and bias than shorter term outcomes due to
loss of follow up and reliance on self reported data. Such
misclassification may have biased our results towards the null.
Additionally, it is possible that women may have had prior
M genitalium infection that resulted in tubal damage preceding
the baseline PEACH study PID episode. As such prior infection
would not be identified using PCR, which identifies acute
infection, this may have biased our results towards the null.
Indeed, in a study of 308 women undergoing in vitro
fertilisation treatment, women determined to have tubal factor
infertility were over three times as likely to be seropositive for
M genitalium.
27 Moreover, among a study of 212 couples
attending infertility clinics, although M genitalium was not
detected by PCR in any cervical swab specimens, M genitalium
seropositivity was strongly associated with tubal factor
infertility.
28 This supports the idea that previous M genitalium
infection may result in permanent damage and occlusion of
fallopian tubes. Lastly, although we found M genitalium to be
associated with treatment failure, we have previously reported
that short-term markers, including pelvic tenderness at 5 and 30
days, are not predictive of reproductive morbidity in the PEACH
study population.
29 As over two-thirds of women in the PEACH
study presented for treatment with 3 or more days of pelvic
pain,
7 and since delayed care for PID is associated with almost a
threefold increased risk for infertility,
30 all women in the PEACH
study may have been at increased risk for reproductive sequelae
regardless of short-term treatment response. Indeed, women in
the PEACH study experienced distressingly high rates of
morbidity regardless of microbial aetiology of PID (infertility
17%,
7 recurrent PID 14%
7 and chronic pelvic pain 37%
31).
Table 2 Endometritis 30 days following treatment with cefoxitin and doxycycline and short-term treatment failure (endometritis at 30 days and
persistent pelvic pain) among women with and without baseline Mycoplasma genitalium (MG) genital tract infection
Outcome
Cervical and/or
endometrial Mg+ n
(%) n=88
Cervical and/or
endometrial Mg2 n
(%) n=498
Adjusted RR"
(95% CI)
Endometrial Mg+ n
(%) n=50
Endometrial Mg2 n
(%) n=561 Adjusted RR" (95% CI)
Treatment failure* 8 (40.0) 26 (17.5) 2.6 (0.8 to 8.9) 6 (50.0) 30 (18.5) 4.6 (1.1 to 20.1)
Endometritis at 30 days{ 25 (56.8) 119 (39.0) 1.9 (0.9 to 3.9) 19 (70.4) 131 (39.2) 4.0 (1.5 to 10.9)
Incident endometritis{ 6 (24.0) 35 (15.8) 1.5 (0.4 to 5.0) 5 (38.5) 37 (15.4) 5.0 (1.2 to 20.6)
Persistent endometritis1 17 (47.2) 73 (28.2) 2.1 (1.0 to 4.6) 13 (61.9) 82 (28.8) 4.1 (1.4 to 11.9)
*Treatment failure is defined as both endometritis and pelvic pain present at the 30 day clinic visit; {All women categorised as having endometritis at the 30 day clinic visit;
{includes women without endometritis at baseline who are categorised as having endometritis at the 30 day clinic visit; 1includes women who are categorised as having
endometritis at both baseline and 30 days; "Adjusted for age and race, self reported partner treatment and intercourse between baseline and the 30 day clinic visit.
Table 3 Sequelae and long-term treatment failure among women with and without baseline Mycoplasma gentalium (MG) genital tract infection
Outcome
Cervical and/or
endometrial Mg+ n (%)
n=88
Cervical and/or
endometrial Mg2 n (%)
n=498
Adjusted RR*
(95% CI)
Endometrial Mg+ n (%)
n=50
Endometrial Mg2 n (%)
n=561
Adjusted RR*
(95% CI)
Recurrent pelvic
inflammatory disease
24 (28.2) 98 (20.8) 1.6 (0.8 to 3.1) 15 (30.6) 111 (20.8) 1.8 (0.8, 3.8)
Infertility 15 (17.4) 95 (19.4) 1.4 (0.6 to 2.9) 11 (22.0) 104 (18.9) 1.1 (0.7 to 4.0)
Chronic pelvic pain 37 (43.5) 198 (41.4) 1.6 (0.9 to 2.9) 21 (42.0) 226 (42.1) 1.3 (0.6 to 2.7)
Pregnancy 53 (61.6) 278 (56.9) 0.8 (0.4 to 1.5) 29 (58.0) 317 (57.6) 0.7 (0.3 to 1.4)
Live birth 34 (50.7) 207 (48.5) 0.7 (0.3 to 1.3) 19 (46.3) 236 (49.3) 0.6 (0.3 to 1.3)
*All models are adjusted for age, race, Neisseria gonorrhoeae and Chlamydia trachomatis. Infertility, pregnancy and live birth models are additionally adjusted for self reported
infertility at baseline.
Clinical
Sex Transm Infect 2008;84:338–342. doi:10.1136/sti.2008.030486 341Certainly, women with M genitalium identified in either the
cervix or endometrium had high rates of infertility (18%),
recurrent PID (28%) and chronic pelvic pain (44%). These
infertility rates are approximately 2.5 times higher than that
reported from a study utilising 2002 National Survey of Family
Growth data,
32 suggesting that preservation of fertility may be
suboptimal for many women treated for PID.
Recommended PID treatment regimens are based on clinical
trial data demonstrating overall high rates of clinical cure. PID is
well recognised though as having a polymicrobial aetiology, and
not all microbial infections may respond equally well to the
same antimicrobial. In our study of women with clinically
suspected PID, we found M genitalium to be associated with
endometritis and short-term PID treatment failure, as evidenced
by persistent endometritis and continued pelvic pain. We
conclude that cefoxitin and doxycycline, a Center for Disease
Control recommended PID treatment regimen, is ineffective for
the treatment of M genitalium upper genital tract infection.
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Key messages
c Mycoplasma genitalium is frequently detected from the cervix
and endometrium of women with clinically suspected pelvic
inflammatory disease (PID).
c M genitalium is associated with endometritis and short-term
PID treatment failure, as evidenced by persistent endometritis
and continued pelvic pain.
c Cefoxitin and doxycycline, a Center for Disease Control
recommended PID treatment regimen, is ineffective for the
treatment of M genitalium upper genital tract infection.
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